NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblast’s presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at An archived webcast of the conference presentation will be available for 90 days on the Company’s website at

View post:
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *